| YNe | therapeutic agents d-out qh |
| HN | ETOH descriptor 2000. | |
| NT | +YPe anti-AOD-abuse agents qh ah | |
| +YQ anti-inflammatory, anti-infective, and antineoplastic agents qh ah | ||
| +YR analgesics and anesthetics qh ah | ||
| +YS reproductive control agents qh ah | ||
| +YTe agents used in body system disorders qh ah | ||
| RT | +EBe metabolism qh ah | |
| +EB10e drug metabolism qh ah | ||
| +EE14.4.4.2e therapeutic drug effect qh ah |
| YPe | anti-AOD-abuse agents d-out qh |
| SN | This section lists pharmacologic agents used in or tested for various facets of the treatment of AOD abuse, its causes, and its consequences. The section begins with a classification of treatment functions that is used throughout, keeping in mind that many of these treatment functions overlap and that many agents are used in multiple functions. The section then is organized by substance or substance class being abused. If the agent being discussed is used in treating abuse of a substance that does not fall into any of the substance classes, use the generic treatment function descriptor combined with the descriptor for the substance. | |
| ST | pharmacologic agents for AODD | |
| BT | +YNe therapeutic agents qh ah | |
| RT | +GCe AODD qh ah | |
| +HK2.10 AODD drug therapy qh ah |
| YP2 | . anti-AOD-abuse agents by function qh |
| HN | Introduced 1995. |
| YP2.2e | . . anti-AOD-intoxication agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| NT | +YP4.2e anti-alcohol-intoxication agents qh ah | |
| YP6.2 anti-sedative-hypnotic-intoxication agents qh ah | ||
| YP10.2 anti-cocaine-intoxication agents qh ah | ||
| +YP12.2 anti opiate intoxication agents qh ah |
| YP2.4e | . . AOD detoxification agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| NT | YP4.4e alcohol detoxification agents qh ah | |
| YP6.4 sedative-hypnotic detoxification agents qh ah | ||
| +YP8.4 nicotine detoxification agent qh ah | ||
| YP10.4 cocaine detoxification agents qh ah | ||
| +YP12.4 opiate detoxification agents qh ah |
| YP2.6e | . . AOD withdrawal agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| SN | Agents for the treatment of acute AOD withdrawal and its symptoms, including substances tested for alleviation of hangover. Protracted withdrawal may cause mental/psychiatric symptoms or lead to the reemergence of preexisting mental disorders that must be treated; see *+YP2.8.12 agents for AOD-concurrent mental disorders* qh ah. | |
| NT | +YP4.6e alcohol withdrawal agents qh ah | |
| +YP6.6 sedative-hypnotic withdrawal agents qh ah | ||
| YP8.6 nicotine withdrawal agents qh ah | ||
| YP10.6 cocaine withdrawal agents qh ah | ||
| +YP12.6 opiate withdrawal agents qh ah |
| YP2.8e | . . AOD relapse prevention agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| ST | AOD dependent maintenance agents | |
| NT | +YP4.8e alcohol relapse prevention agents qh ah | |
| +YP6.8 sedative-hypnotic relapse prevention agents qh ah | ||
| +YP8.8 nicotine relapse prevention agents qh ah | ||
| +YP10.8 cocaine relapse prevention agents qh ah | ||
| +YP12.8 opiate relapse prevention agents qh ah | ||
| YW6.2.2e tianeptine qh ah | ||
| RT | +AH20e AODD relapse qh ah |
| YP2.8.2e | . . . anti-AOD-craving agents qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| ST | anticraving agents | |
| NT | +YP4.8.2e anti-alcohol-craving agents qh ah | |
| YP6.8.2 anti-sedative-hypnotic-craving agents qh ah | ||
| YP8.8.2 anti-nicotine-craving agents qh ah | ||
| +YP10.8.2 anti-cocaine-craving agents qh ah | ||
| YP12.8.2 anti-opiate-craving agents qh ah |
| YP2.8.4 | . . . AOD agonist maintenance agents qh |
| HN | Introduced 1995. | |
| NT | YP4.8.4 alcohol agonist maintenance agents qh ah | |
| YP8.8.4 nicotine agonist maintenance agents qh ah | ||
| YP10.8.4 cocaine agonist maintenance agents qh ah | ||
| +YP12.8.4 opiate agonist maintenance agents qh ah |
| YP2.8.6 | . . . AOD blockers qh |
| HN | Introduced 1995. | |
| ST | AOD antagonists | |
| NT | +YP4.8.6e alcohol blockers qh ah | |
| YP6.8.4 sedative-hypnotic blockers qh ah | ||
| +YP8.8.6 nicotine blockers qh ah | ||
| +YP10.8.6 cocaine blockers qh ah | ||
| +YP12.8.6 opiate blockers qh ah |
| YP2.8.8 | . . . AOD deterrents qh |
| HN | Introduced 1995. | |
| SN | Substances that alter the body's response to an AOD substance, making ingestion of the substance unpleasant or toxic. | |
| ST | AOD aversive agents | |
| AOD sensitizing agents | ||
| NT | +YP4.8.8e alcohol deterrents qh ah | |
| YP6.8.6 sedative-hypnotic deterrents qh ah | ||
| YP8.8.8 nicotine deterrents qh ah | ||
| YP10.8.8 cocaine deterrents qh ah | ||
| YP12.8.8 opiate deterrents qh ah |
| YP2.8.10 | . . . conditioned AOD aversion agents qh |
| HN | Introduced 1995. | |
| SN | Substances that have unpleasant effects and are given together with an AOD substance. | |
| NT | +YP4.8.10e conditioned alcohol aversion agents qh ah |
| YP2.8.12 | . . . agents for AOD-concurrent mental disorders qh |
| HN | Introduced 1995. | |
| SN | The mental disorder may be primary (i.e., preexisting and underlying AOD abuse) or secondary (i.e., induced by AOD abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| ST | agents for mental disorder leading to AOD abuse | |
| agents for mental disorder resulting from AOD abuse | ||
| NT | +YP4.8.12e agents for alcohol-concurrent mental disorders qh ah | |
| +YP6.8.8 agents for sedative-hypnotic-concurrent mental disorders qh ah | ||
| YP8.8.10 agents for nicotine-concurrent mental disorders qh ah | ||
| +YP10.8.10 agents for cocaine-concurrent mental disorders qh ah | ||
| +YP12.8.10 agents for opiate-concurrent mental disorders qh ah | ||
| RT | +YP2.6e AOD withdrawal agents qh ah |
| YP2.8.12.2 | . . . . agents for AOD-concurrent depression qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | |
| YP6.8.8.2 agents for sedative-hypnotic-concurrent depression qh ah | ||
| +YP10.8.10.2 agents for cocaine-concurrent depression qh ah | ||
| YP12.8.10.2 agents for opiate-concurrent depression qh ah | ||
| YW6.2.2e tianeptine qh ah | ||
| BT | +YW6e antidepressants qh ah |
| YP2.8.12.4 | . . . . agents for AOD-concurrent anxiety qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.8 agents for alcohol-concurrent anxiety qh ah | |
| YP6.8.8.4 agents for sedative-hypnotic-concurrent anxiety qh ah | ||
| +YP10.8.10.4 agents for cocaine-concurrent anxiety qh ah | ||
| YP12.8.10.4 agents for opiate-concurrent anxiety qh ah | ||
| BT | +YW4.10e tranquilizers qh ah |
| YP2.8.12.6 | . . . . agents for AOD-related cognitive impairment qh |
| HN | Introduced 1995. | |
| NT | +YP4.8.12.10 agents for alcohol-related cognitive impairment qh ah | |
| YP6.8.8.6 agents for sedative-hypnotic-related cognitive impairment qh ah | ||
| +YP10.8.10.6 agents for cocaine-related cognitive impairment qh ah | ||
| YP12.8.10.6 agents for opiate-related cognitive impairment qh ah |
| YP4e | . anti-alcohol-abuse agents qh |
| HN | ETOH descriptor 2000. | |
| ST | pharmacologic agents for alcoholism treatment |
| YP4.2e | . . anti-alcohol-intoxication agents qh |
| ST | amethystic agents | |
| NT | +YH2.4.32e vasopressin qh ah | |
| ZJ2.6.8e ibuprofen qh ah | ||
| +ZJ2.6.10.4.4.2.2e disulfiram qh ah | ||
| ZN2.12e fluvoxamine qh ah | ||
| ZQ4.6.4e naloxone qh ah | ||
| ZT4.6.6e atipamezole qh ah | ||
| ZT6.8.2.2.2.2e daidzin qh ah | ||
| ZT6.8.2.2.2.4e puerarin qh ah | ||
| BT | +YP2.2e anti-AOD-intoxication agents qh ah | |
| RT | +YL2.4 ethanol antagonists qh ah |
| YP4.4e | . . alcohol detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP4.6e | . . alcohol withdrawal agents qh |
| SN | Agents for the treatment of acute alcohol withdrawal and its symptoms, including substances tested for alleviation of hangover (e.g., pyritinol). Protracted withdrawal may cause mental/psychiatric symptoms or lead to the reemergence of preexisting mental disorders that must be treated; see agents for alcohol concurrent mental disorders. | |
| NT | ZA2.4.2.2e lithium qh ah | |
| ZC12.8.10e nitrous oxide qh ah | ||
| ZF2.4.2.4 chloral hydrate qh ah | ||
| ZF4.2e caroverine qh ah | ||
| ZP8.4e bromocriptine qh ah | ||
| ZP32.2e apomorphine qh ah | ||
| ZT4.6.4e chlormethiazole qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| +ZT4.26.2.6e dihydropyridine qh ah | ||
| ZT4.26.2.10e nifedipine qh ah | ||
| ZT4.26.12e pyrithioxin qh ah | ||
| +ZT4.28.6.6e barbiturates qh ah | ||
| ZT4.28.6.6.12e phenobarbital qh ah | ||
| +ZT8.4.2e carbamazepine qh ah | ||
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | +YP4.8.2e anti-alcohol-craving agents qh ah | |
| +YT8.14e calcium channel blockers qh ah | ||
| +YV14.2.2e alpha-adrenergic receptor agonists qh ah |
| YP4.6.2e | . . . lofexidine qh |
| HN | ETOH descriptor 2000. |
| YP4.6.4e | . . . slumazenil qh |
| HN | ETOH descriptor 2000. |
| YP4.6.6 | . . . beta blockers for alcohol withdrawal qh |
| NT | ZN2.16.2.12.4.2e propranolol qh ah | |
| ZN2.16.2.18e atenolol qh ah |
| YP4.6.8e | . . . benzodiazepines for alcohol withdrawal qh |
| HN | ETOH descriptor 2000. | |
| NT | ZT6.4.2.2e alprazolam qh ah | |
| ZT6.4.2.8.8e clonazepam qh ah | ||
| +ZT6.4.2.8.12e diazepam qh ah | ||
| ZT6.4.2.8.18e flurazepam qh ah | ||
| ZT6.4.2.8.20e lorazepam qh ah | ||
| ZT6.4.2.8.24e oxazepam qh ah | ||
| ZT6.4.2.8.28e prazepam qh ah | ||
| ZT6.4.2.8.30e temazepam qh ah | ||
| ZT6.4.2.8.32e halazepam qh ah | ||
| +ZT6.4.2.10e chlordiazepoxide qh ah | ||
| ZT6.4.2.10.2e clorazepate qh ah | ||
| BT | +ZT6.4.2e benzodiazepines qh ah |
| YP4.6.10 | . . . anti-alcohol-related-delirium agents qh |
| NT | ZG4.4.2e haloperidol qh ah |
| YP4.6.12 | . . . anti-alcohol-related-seizures agents qh |
| NT | ZG8.4.4e valproic acid qh ah | |
| ZT4.14.6.2e phenytoin qh ah | ||
| ZT4.28.6.6.12e phenobarbital qh ah | ||
| +ZT8.4.2e carbamazepine qh ah |
| YP4.8e | . . alcohol relapse prevention agents qh |
| ST | alcohol dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP4.8.2e | . . . anti-alcohol-craving agents qh |
| ST | alcohol intake reduction agents | |
| anti-dipsotropic agents | ||
| NT | YH2.2.2e melatonin qh ah | |
| ZT6.8.2.2.2.2e daidzin qh ah | ||
| ZT6.8.2.2.2.4e puerarin qh ah | ||
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | +YP4.6e alcohol withdrawal agents qh ah |
| YP4.8.2.2e | . . . . serotonergic anti-alcohol-craving agents qh |
| HN | ETOH descriptor 2000. | |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| YV6.6.2.2 viqualine qh ah | ||
| ZF8.6.2.2.2e sertraline qh ah | ||
| ZN2.4.2e fluoxetine qh ah | ||
| ZN2.4.4e citalopram qh ah | ||
| ZN2.12e fluvoxamine qh ah | ||
| +ZT4.26.4.2.2e zimelidine qh ah | ||
| ZT4.26.4.2.2.2e norzimelidine qh ah | ||
| ZT4.28.2e buspirone qh ah |
| YP4.8.2.2.2e | . . . . . alaproclate qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.2.4e | . . . . . femoxetine qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.2.6e | . . . . . indalpine qh |
| HN | ETOH descriptor 2000. |
| YP4.8.2.4 | . . . . dopaminergic anti-alcohol-craving agents qh |
| NT | ZP8.4e bromocriptine qh ah |
| YP4.8.2.6 | . . . . GABA receptor agonist anti-alcohol-craving agents qh |
| NT | ZJ2.10.4.2e gamma-hydroxybutyric acid qh ah | |
| ZJ2.10.8.2.2.2.2e calcium acetylhomotaurinate qh ah | ||
| ZJ2.10.8.2.2.2.4e bis acetyl homotaurine qh ah |
| YP4.8.2.8 | . . . . narcotic antagonist anti-alcohol-craving agents qh |
| NT | ZQ4.6.4e naloxone qh ah | |
| ZQ4.6.6e naltrexone qh ah | ||
| ZQ4.8.6e nalmefene qh ah | ||
| ZT4.14.10 ondansetron qh ah |
| YP4.8.2.10 | . . . . neuropeptide anti-alcohol-craving agents qh |
| NT | YH2.4.2e thyrotropin RH qh ah | |
| YH2.4.14e adrenocorticotropic hormone qh ah | ||
| +YH2.4.32e vasopressin qh ah | ||
| YH2.4.36e cholecystokinin qh ah | ||
| YV6.6.2.4 amterozide qh ah | ||
| ZT4.28.6.4e ritanserin qh ah | ||
| BT | +ZO4.24e neuropeptides qh ah |
| YP4.8.4 | . . . alcohol agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP4.8.6e | . . . alcohol blockers qh |
| HN | ETOH descriptor 2000. | |
| ST | alcohol antagonists | |
| NT | ZQ4.6.6e naltrexone qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP4.8.8e | . . . alcohol deterrents qh |
| HN | ETOH descriptor 2000. | |
| SN | Substances that alter the body's response to alcohol, making its ingestion unpleasant or toxic. | |
| ST | alcohol aversive agents | |
| alcohol sensitizing agents | ||
| antidipsotropic agents | ||
| NT | ZC12.6.2.2e citrated calcium carbimide qh ah | |
| +ZJ2.6.10.4.4.2.2e disulfiram qh ah | ||
| ZT4.6.8e nitrefazole qh ah | ||
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP4.8.10e | . . . conditioned alcohol aversion agents qh |
| HN | ETOH descriptor 2000. | |
| SN | Substances that have unpleasant effects and are given together with alcohol. | |
| NT | +ZN2.16.2.10.2e succinylcholine qh ah | |
| ZP32.2e apomorphine qh ah | ||
| ZT6.12.2e emetine qh ah | ||
| BT | +YP2.8.10 conditioned AOD aversion agents qh ah |
| YP4.8.12e | . . . agents for alcohol-concurrent mental disorders qh |
| HN | ETOH descriptor 2000. | |
| SN | The mental disorder may be primary (i.e., preexisting and underlying alcohol abuse) or secondary (i.e., induced by alcohol abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP4.8.12.2 | . . . . dopaminergic blockers for alcohol-concurrent mental disorders qh |
| NT | ZN2.20.6.4e tiapride qh ah | |
| ZT8.14.12e thioridazine qh ah |
| YP4.8.12.4 | . . . . dopaminergic agonists for alcohol-concurrent mental disorders qh |
| NT | ZP8.4e bromocriptine qh ah | |
| ZP32.2e apomorphine qh ah |
| YP4.8.12.6 | . . . . agents for alcohol-concurrent depression qh |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| +YW6.4e MAO inhibitors qh ah | ||
| ZA2.4.2.2e lithium qh ah | ||
| ZF8.10.2.2e amitriptyline qh ah | ||
| ZN2.4.2e fluoxetine qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.8.2e doxepin qh ah | ||
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP4.8.12.8 | . . . . agents for alcohol-concurrent anxiety qh |
| NT | YW6.4.2 phenelzine qh ah | |
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| ZT4.28.2e buspirone qh ah | ||
| +ZT6.4.2e benzodiazepines qh ah | ||
| ZT6.4.2.2e alprazolam qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP4.8.12.10 | . . . . agents for alcohol-related cognitive impairment qh |
| NT | +YV6.6.2e serotonin uptake inhibitors qh ah | |
| ZN2.12e fluvoxamine qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP4.8.12.10.2 | . . . . . piridoxilate qh |
| YP6 | . anti-sedative-hypnotic-abuse agents qh |
| SN | Agents mentioned here may also apply to alcohol dependence. |
| YP6.2 | . . anti-sedative-hypnotic-intoxication agents qh |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP6.4 | . . sedative-hypnotic detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP6.6 | . . sedative-hypnotic withdrawal agents qh |
| SN | Agents for the treatment of acute sedative-hypnotic withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated, see *+YP6.8.8 agents for sedative-hypnotic-concurrent mental disorders* qh ah. | |
| BT | +YP2.6e AOD withdrawal agents qh ah |
| YP6.6.2 | . . . barbiturate withdrawal agents qh |
| NT | ZT4.28.6.6.10e pentobarbital qh ah | |
| ZT4.28.6.6.12e phenobarbital qh ah |
| YP6.6.4 | . . . benzodiazepine withdrawal agents qh |
| NT | +ZT6.4.2.8.12e diazepam qh ah |
| YP6.8 | . . sedative-hypnotic relapse prevention agents qh |
| ST | sedative-hypnotic dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP6.8.2 | . . . anti-sedative-hypnotic-craving agents qh |
| ST | sedative-hypnotic intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah |
| YP6.8.4 | . . . sedative-hypnotic blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of sedative-hypnotics. | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP6.8.6 | . . . sedative-hypnotic deterrents qh |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP6.8.8 | . . . agents for sedative-hypnotic-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying sedative-hypnotic abuse) or secondary (i.e., induced by sedative-hypnotic abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP6.8.8.2 | . . . . agents for sedative-hypnotic-concurrent depression qh |
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP6.8.8.4 | . . . . agents for sedative-hypnotic-concurrent anxiety qh |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP6.8.8.6 | . . . . agents for sedative-hypnotic-related cognitive impairment qh |
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP8 | . anti-nicotine-abuse agents qh |
| NT | ZT4.14.2e clonidine qh ah |
| YP8.2 | . . busprione qh |
| YP8.4 | . . nicotine detoxification agent qh |
| ST | nicotine substitution agents | |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP8.4.2 | . . . nicotin gum qh |
| YP8.6 | . . nicotine withdrawal agents qh |
| SN | Agents for the treatment of acute nicotine withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for nicotine concurrent mental disorders. | |
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | YP8.8.2 anti-nicotine-craving agents qh ah |
| YP8.8 | . . nicotine relapse prevention agents qh |
| ST | nicotine dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP8.8.2 | . . . anti-nicotine-craving agents qh |
| ST | nicotine intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | YP8.6 nicotine withdrawal agents qh ah |
| YP8.8.4 | . . . nicotine agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP8.8.6 | . . . nicotine blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of nicotine. | |
| ST | nicotine antagonist maintenance agents | |
| NT | ZU6.2e mecamylamine qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah |
| YP8.8.8 | . . . nicotine deterrents qh |
| ST | nicotine aversive agents | |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP8.8.10 | . . . agents for nicotine-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying nicotine abuse) or secondary (i.e., induced by nicotine abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP10 | . anti-cocaine-abuse agents qh |
| YP10.2 | . . anti-cocaine-intoxication agents qh |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP10.4 | . . cocaine detoxification agents qh |
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP10.6 | . . cocaine withdrawal agents qh |
| SN | Agents for the treatment of acute cocaine withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for cocaine concurrent mental disorders. | |
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | +YP10.8.2 anti-cocaine-craving agents qh ah |
| YP10.8 | . . cocaine relapse prevention agents qh |
| ST | cocaine dependent maintenance agents | |
| NT | ZQ6.2e buprenorphine qh ah | |
| +ZT8.4.2e carbamazepine qh ah | ||
| ZT8.16.2.2e flupenthixol qh ah | ||
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP10.8.2 | . . . anti-cocaine-craving agents qh |
| NT | ZF8.2 amantadine qh ah | |
| +ZO2e amino acids qh ah | ||
| ZO2.2.2.14e tryptophan qh ah | ||
| ZO2.2.4.10e tyrosine qh ah | ||
| ZT6.4.2.6e carbamazepin qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.16.2.2e flupenthixol qh ah | ||
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | YP10.6 cocaine withdrawal agents qh ah |
| YP10.8.2.2 | . . . . bupropion qh |
| YP10.8.4 | . . . cocaine agonist maintenance agents qh |
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah |
| YP10.8.6 | . . . cocaine blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of cocaine. | |
| ST | cocaine antagonist maintenance agents | |
| NT | ZG4.4.2e haloperidol qh ah | |
| ZP8.4e bromocriptine qh ah | ||
| ZT4.18.4e trazodone qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| BT | +YP2.8.6 AOD blockers qh ah | |
| RT | +YV6 neuroregulator blockaders qh ah |
| YP10.8.8 | . . . cocaine deterrents qh |
| ST | cocaine aversive agents | |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP10.8.10 | . . . agents for cocaine-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying cocaine abuse) or secondary (i.e., induced by cocaine abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| NT | ZJ2.4e methylphenydate qh ah | |
| ZT4.16.4.2e magnesium pemoline qh ah | ||
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP10.8.10.2 | . . . . agents for cocaine-concurrent depression qh |
| NT | ZF8.4 maprotiline qh ah | |
| ZT4.18.4e trazodone qh ah | ||
| ZT8.2.2.4e imipramine qh ah | ||
| ZT8.2.2.6e desipramine qh ah | ||
| ZT8.8.2e doxepin qh ah | ||
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP10.8.10.4 | . . . . agents for cocaine-concurrent anxiety qh |
| NT | ZT8.2.2.6e desipramine qh ah | |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP10.8.10.6 | . . . . agents for cocaine-related cognitive impairment qh |
| SN | *GZ12.2.2 attention deficit disorder with hyperactivity* qh ah in particular is associated with cocaine abuse. | |
| NT | ZJ2.10.4.8e methylphenidate qh ah | |
| ZT4.16.4.2e magnesium pemoline qh ah | ||
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YP12 | . anti-opiate-abuse agents qh |
| YP12.2 | . . anti opiate intoxication agents qh |
| NT | ZQ4.6.4e naloxone qh ah | |
| BT | +YP2.2e anti-AOD-intoxication agents qh ah |
| YP12.4 | . . opiate detoxification agents qh |
| NT | ZQ4.6.6e naltrexone qh ah | |
| +ZQ10.2e methadone qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.4e AOD detoxification agents qh ah |
| YP12.6 | . . opiate withdrawal agents qh |
| SN | Agents for the treatment of acute opiate withdrawal. Protracted withdrawal may cause mental/psychiatric symptoms that must be treated; see agents for opiate concurrent mental disorders. | |
| NT | +ZQ10.2e methadone qh ah | |
| ZT4.14.2e clonidine qh ah | ||
| BT | +YP2.6e AOD withdrawal agents qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8 | . . opiate relapse prevention agents qh |
| ST | opiate dependent maintenance agents | |
| BT | +YP2.8e AOD relapse prevention agents qh ah |
| YP12.8.2 | . . . anti-opiate-craving agents qh |
| ST | opiate intake reduction agents | |
| BT | +YP2.8.2e anti-AOD-craving agents qh ah | |
| RT | +YP12.6 opiate withdrawal agents qh ah | |
| +YP12.8.4 opiate agonist maintenance agents qh ah | ||
| +YP12.8.6 opiate blockers qh ah |
| YP12.8.4 | . . . opiate agonist maintenance agents qh |
| NT | ZQ6.2e buprenorphine qh ah | |
| +ZQ10.2e methadone qh ah | ||
| ZQ10.4e LAAM qh ah | ||
| BT | +YP2.8.4 AOD agonist maintenance agents qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8.6 | . . . opiate blockers qh |
| SN | Agents that block the mood-altering or analgesic effects of opiates. | |
| ST | opiate antagonist maintenance agents | |
| NT | ZQ4.6.6e naltrexone qh ah | |
| BT | +YP2.8.6 AOD blockers qh ah | |
| RT | YP12.8.2 anti-opiate-craving agents qh ah |
| YP12.8.8 | . . . opiate deterrents qh |
| BT | +YP2.8.8 AOD deterrents qh ah |
| YP12.8.10 | . . . agents for opiate-concurrent mental disorders qh |
| SN | The mental disorder may be primary (i.e., preexisting and underlying opiate abuse) or secondary (i.e., induced by opiate abuse), or symptoms may be caused by or occur with acute and protracted withdrawal. Treatment of these disorders centers mostly on relapse prevention. | |
| BT | +YP2.8.12 agents for AOD-concurrent mental disorders qh ah |
| YP12.8.10.2 | . . . . agents for opiate-concurrent depression qh |
| BT | +YP2.8.12.2 agents for AOD-concurrent depression qh ah | |
| +YW6e antidepressants qh ah |
| YP12.8.10.4 | . . . . agents for opiate-concurrent anxiety qh |
| BT | +YP2.8.12.4 agents for AOD-concurrent anxiety qh ah | |
| +YW4.10e tranquilizers qh ah |
| YP12.8.10.6 | . . . . agents for opiate-related cognitive impairment qh |
| BT | +YP2.8.12.6 agents for AOD-related cognitive impairment qh ah |
| YQ | anti-inflammatory, anti-infective, and antineoplastic agents d-out qh |
| BT | +YNe therapeutic agents qh ah |
| YQ2e | . anti-inflammatory agents qh |
| ST | tissue protective agents | |
| tissue repair agents | ||
| NT | ZN2.18.2.2.2.2.2e R alpha methylhistamine qh ah |
| YQ2.2 | . . nonsteroidal anti-inflammatory drugs qh |
| ST | NSAID | |
| NT | +YR2.2.6 gout suppressants qh ah | |
| +ZJ2.10.10.2.4.2.4e salicylate qh ah | ||
| ZT4.24.4e antipyrine qh ah | ||
| ZT4.30.12e tolmetin qh ah | ||
| ZT4.34.2e piroxicam qh ah | ||
| ZT6.10.6e indomethacin qh ah |
| YQ2.4 | . . steroidal anti-inflammatory drugs qh |
| NT | YH4.6.2.2e dexamethasone qh ah | |
| ZV8.2.2.2e prednisone qh ah | ||
| ZV8.2.4.2e prednisolone qh ah | ||
| RT | +ZVe steroids qh ah |
| YQ4e | . anti-infective agents qh |
| NT | +YT12.2 urinary anti-infective agents qh ah | |
| +ZN2.20.8e sulfonamide qh ah |
| YQ4.2 | . . local anti-infective agents qh |
| NT | ZJ2.6.10.4.4.4.2e thiram qh ah |
| YQ4.4 | . . antitubercular agents qh |
| NT | ZF6.6e isoniazid qh ah | |
| RT | +GH16.14.4.2e tuberculosis qh ah |
| YQ4.6 | . . antibacterial agents qh |
| NT | ZT6.24.2e ciprofloxacin qh ah |
| YQ4.6.2 | . . . leprostatic agents qh |
| NT | YQ4.14.16.2 rifampin qh ah | |
| ZJ2.10.10.6.2.2e thalidomide qh ah | ||
| RT | GH16.14.4.4 Hansen's disease qh ah |
| YQ4.8 | . . antifungal agents qh |
| NT | +YQ4.14.6 antifungal antibiotics qh ah | |
| ZJ2.6.10.4.4.4.2e thiram qh ah |
| YQ4.10 | . . antiparasitic agents qh |
| NT | ZT4.32.4e kainate qh ah |
| YQ4.10.2 | . . . anthelmintics qh |
| YQ4.10.4 | . . . antiprotozoal agents qh |
| YQ4.10.4.2 | . . . . antimalarials qh |
| NT | ZP4.4e quinine qh ah | |
| ZT4.28.4e pyrimethamine qh ah | ||
| ZT8.2.2.2e quinacrine qh ah |
| YQ4.12 | . . antiviral agents qh |
| NT | YE10.8.4e interferon qh ah |
| YQ4.12.2 | . . . acyclovir qh |
| YQ4.14e | . . antibiotics qh |
| NT | YD8.12.2e ionophores qh ah | |
| ZF2.4.2.8.2e chloramphenicol qh ah |
| YQ4.14.2 | . . . aminoglycoside antibiotics qh |
| NT | +ZG8.2.2.2e gentamicin qh ah | |
| ZG8.2.2.4e neomycin qh ah |
| YQ4.14.4 | . . . antitubercular antibiotics qh |
| NT | YQ4.14.16.2 rifampin qh ah |
| YQ4.14.6 | . . . antifungal antibiotics qh |
| NT | ZT4.20.8.2e cycloheximide qh ah | |
| BT | +YQ4.8 antifungal agents qh ah |
| YQ4.14.6.2 | . . . . griseofulvin qh |
| BT | +YD8.2 ADH antagonists qh ah |
| YQ4.14.6.4 | . . . . nystatin qh |
| YQ4.14.8 | . . . antineoplastic antibiotics qh |
| BT | +YQ6 antineoplastic agents qh ah |
| YQ4.14.10 | . . . lactam antibiotics qh |
| YQ4.14.10.2 | . . . . moxalactam qh |
| YQ4.14.10.4 | . . . . penicillin qh |
| YQ4.14.10.4.2 | . . . . . penicillin G qh |
| ST | penicillin G benzathine | |
| penicillin G procaine |
| YQ4.14.12 | . . . macrolide antibiotics qh |
| YQ4.14.12.2 | . . . . amphotericin qh |
| YQ4.14.12.4 | . . . . erythromycin qh |
| YQ4.14.14 | . . . bacitracin qh |
| YQ4.14.16 | . . . rifamycins qh |
| YQ4.14.16.2 | . . . . rifampin qh |
| BT | +YQ4.6.2 leprostatic agents qh ah | |
| +YQ4.14.4 antitubercular antibiotics qh ah |
| YQ4.14.18e | . . . tetracyclines qh |
| HN | ETOH descriptor 2000. |
| YQ4.14.20 | . . . combined antibiotics qh |
| YQ6 | . antineoplastic agents qh |
| ST | anti-neoplastic agents | |
| NT | YQ4.14.8 antineoplastic antibiotics qh ah | |
| ZJ2.6.10.4.6e urethane qh ah | ||
| ZN2.20.6.8e procarbazine qh ah | ||
| ZT8.2.2.2e quinacrine qh ah | ||
| ZV8.2.2.2e prednisone qh ah | ||
| RT | YE12e immunosuppressive agents qh ah |
| YR | analgesics and anesthetics d-out qh |
| HN | Introduced 1995. | |
| BT | +YNe therapeutic agents qh ah |
| YR2e | . analgesics qh |
| SN | Substances that reduce pain and that may or may not have other psychoactive properties. See *+ZQ opioids* qh ah.
Drugs that relieve pain without blocking the conduction of nerve impulses or markedly altering the function of the sensory apparatus. The narcotic analgesics act on the central nervous system, produce dependence, and alter the patient's perception; they are primarily used for severe pain. The nonnarcotic analgesics act at the site of pain, do not produce dependence, and do not alter the patient's perception; they are used for mild to moderate pain. | |
| NT | +YW4.2e narcotic analgesics qh ah | |
| ZJ2.10.10.4.2e tilidine qh ah | ||
| RT | GC2.6 abuse of non-dependence-producing substance qh ah | |
| +HU2e analgesia qh ah |
| YR2.2 | . . nonnarcotic analgesics qh |
| SN | The nonnarcotic analgesics act at the site of pain, do not produce dependence, and do not alter the patient's perception; they are used for mild to moderate pain. | |
| ST | anti-inflammatory analgesics | |
| non-opioid analgesics | ||
| NT | +ZJ2.10.10.2.4.2.4e salicylate qh ah | |
| ZT4.24.4e antipyrine qh ah | ||
| ZT4.30.12e tolmetin qh ah | ||
| ZT4.34.2e piroxicam qh ah |
| YR2.2.2 | . . . prescription nonnarcotic analgesics qh |
| HN | Introduced 1995. |
| YR2.2.4 | . . . non-prescription nonnarcotic analgesics qh |
| HN | Introduced 1995. |
| YR2.2.6 | . . . gout suppressants qh |
| NT | ZN2.20.2.2.6e phenacetin qh ah | |
| ZP6e colchicine qh ah | ||
| ZT6.10.6e indomethacin qh ah | ||
| BT | +YQ2.2 nonsteroidal anti-inflammatory drugs qh ah |
| YR2.2.6.2 | . . . . uricosuric agents qh |
| YR4e | . anesthetics qh |
| HN | ETOH descriptor 2000. | |
| SN | Agents that produce a local or general loss of sensation, including pain. Local anesthesia involves loss of sensation in one area of the body by blockage of conduction in nerves. General anesthesia involves loss of consciousness, usually for the purpose of relieving pain during surgery. | |
| NT | +YW4.4e general anesthetics qh ah | |
| ZC12.8.10e nitrous oxide qh ah | ||
| ZF4.4e propofol qh ah | ||
| ZJ2.6.10.2.4.2e sodium oxybate qh ah | ||
| ZL2.6.4e chloroform qh ah | ||
| ZL2.6.8e trichloroethylene qh ah | ||
| +ZT4.28.6.6e barbiturates qh ah | ||
| RT | +HU4e anesthesia qh ah | |
| +YW4.4e general anesthetics qh ah |
| YR4.2e | . . local anesthetics qh |
| HN | ETOH descriptor 2000. | |
| SN | Agents that block conduction in nerve axons in the peripheral nervous system when applied locally to nerve tissue. | |
| ST | anesthetic, local | |
| NT | +BK2e cocaine qh ah | |
| ZJ2.10.10.2.2.2.4e procaine qh ah |
| YS | reproductive control agents d-out qh |
| ST | contraceptive agents | |
| NT | ZK4.4.8.6.2e misoprostol qh ah | |
| BT | +YNe therapeutic agents qh ah | |
| RT | HS4.2e contraception qh ah |
| YS2e | . female contraceptive agents qh |
| ST | birth control pills | |
| NT | ZV6.2e mifepristone qh ah | |
| RT | +YH4.10.4 synthetic progestational hormones qh ah | |
| +ZV22e synthetic steroids qh ah |
| YS4e | . male contraceptive agents qh |
| YTe | agents used in body system disorders d-out qh |
| NT | +YV peripheral nervous system agents qh ah | |
| BT | +YNe therapeutic agents qh ah |
| YT2e | . appetite suppressants qh |
| SN | Agents used to reduce hunger and diminish food intake in the treatment of obesity.
Also called anorexiants or anorectic agents. Most of these drugs are sympathomimetic amines, whose efficacy is limited by associated insomnia, dependence phenomena, and other adverse effects. Amphetamines formerly were used for their appetite-suppressing effects. | |
| ST | anorectic agents | |
| anorexiants | ||
| appetite depressants | ||
| NT | +BJ2.2e amphetamines qh ah | |
| +ZN2.10.2e fenfluramine qh ah |
| YT4 | . antimetabolites qh |
| NT | ZT4.26.10.4e pyrithiamine qh ah | |
| +ZT4.28.6.8.2e thiouracil qh ah | ||
| ZT4.28.6.8.2.2e propylthiouracil qh ah |
| YT6e | . neuromuscular agents qh |
| HN | ETOH descriptor 2000. |
| YT6.2 | . . central muscle relaxants qh |
| NT | ZJ2.6.10.4.2e meprobamate qh ah | |
| ZT6.4.2.8.28e prazepam qh ah |
| YT6.4 | . . neuromuscular blocking agents qh |
| YT6.4.2 | . . . curare qh |
| RT | +ZPe alkaloids qh ah |
| YT6.6 | . . neuromuscular depolarizing agents qh |
| NT | +ZN2.16.2.10.2e succinylcholine qh ah |
| YT8e | . cardiovascular agents qh |
| YT8.2 | . . antiarrhythmia agents qh |
| NT | ZJ2.10.10.2.2.2.2e procainamide qh ah | |
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| ZP4.2e quinidine qh ah | ||
| ZP20e sparteine qh ah | ||
| ZT4.14.6.2e phenytoin qh ah | ||
| RT | +YT8.6e vasodilator agents qh ah |
| YT8.4e | . . vasoconstrictor agents qh |
| HN | Introduced 1995. | |
| ST | vasopressor agents | |
| NT | +YH2.4.6e angiotensin qh ah | |
| +YH2.4.32e vasopressin qh ah | ||
| +YT8.12e calcium channel agonists qh ah | ||
| ZN2.16.2.4e phenylephrine qh ah | ||
| ZN2.16.2.20e methoxamine qh ah | ||
| RT | EL4.10e vasoconstriction qh ah |
| YT8.6e | . . vasodilator agents qh |
| HN | ETOH descriptor 1995. | |
| NT | BC4 theophylline qh ah | |
| +YT8.14e calcium channel blockers qh ah | ||
| ZC12.6.4.2e sodium nitroprusside qh ah | ||
| ZC12.8.6.2e amyl nitrite qh ah | ||
| ZC12.8.6.4e butyl nitrite qh ah | ||
| ZF2.2.4.2e ifenprodil qh ah | ||
| ZF2.12.2.2e nitroglycerin qh ah | ||
| ZF2.12.8.2.2e isosorbide dinitrate qh ah | ||
| ZF4.6e resveratrol qh ah | ||
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| ZN2.16.2.16e suloctidil qh ah | ||
| RT | +YT8.2 antiarrhythmia agents qh ah |
| YT8.8 | . . antihypertensive agents qh |
| ST | hypertensive medication | |
| NT | ZC12.6.4.2e sodium nitroprusside qh ah | |
| ZN2.10.6e phenoxybenzamine qh ah | ||
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| ZO2.2.8.6.2e captopril qh ah | ||
| ZP18.4.4e nimodipine qh ah | ||
| +ZP26e rauwolfia alkaloids qh ah | ||
| ZT4.14.2e clonidine qh ah | ||
| ZT4.14.12e phentolamine qh ah | ||
| ZT4.26.2.6.4e isradipine qh ah | ||
| ZT4.26.2.6.6e nitrendipine qh ah | ||
| ZT6.20.6e prazosin qh ah |
| YT8.10 | . . cardiotonic agents qh |
| NT | +YH2.2.6.6e norepinephrine qh ah | |
| +ZG8.2.6e cardiac glycosides qh ah | ||
| ZN2.16.2.4e phenylephrine qh ah |
| YT8.12e | . . calcium channel agonists qh |
| HN | Introduced 1995. ETOH descriptor 2000. | |
| NT | ZT4.26.2.6.2e Bay K 8644 qh ah | |
| BT | +YT8.4e vasoconstrictor agents qh ah |
| YT8.14e | . . calcium channel blockers qh |
| NT | ZF4.2e caroverine qh ah | |
| ZM4e verapamil qh ah | ||
| ZP18.4.4e nimodipine qh ah | ||
| ZT4.20.6e perhexiline qh ah | ||
| ZT4.26.2.6.4e isradipine qh ah | ||
| ZT4.26.2.6.6e nitrendipine qh ah | ||
| ZT4.26.2.10e nifedipine qh ah | ||
| BT | +YT8.6e vasodilator agents qh ah | |
| RT | +YP4.6e alcohol withdrawal agents qh ah |
| YT10e | . gastrointestinal agents qh |
| NT | YC4.10.4.2e pepsin qh ah | |
| +YG6 gastrointestinal hormones qh ah |
| YT10.2e | . . emetic agents qh |
| HN | Changed descriptor 2000; through 1999 use "emetics." ETOH descriptor 2000. | |
| SN | Agent that causes vomiting. | |
| ST | emetics | |
| BT | +YV6 neuroregulator blockaders qh ah |
| YT10.2.2 | . . . ipecac qh |
| BT | +ZPe alkaloids qh ah | |
| RT | +HK2.12.2e chemical aversion therapy qh ah |
| YT10.4 | . . laxatives qh |
| RT | BN other specific drug of abuse qh ah |
| YT10.6 | . . antidiarrheals qh |
| NT | ZH10e pectin qh ah |
| YT10.8 | . . antiulcer agents qh |
| NT | ZH8.4.2.2e sucralfate qh ah | |
| ZK4.4.8.6.2e misoprostol qh ah | ||
| ZT4.12.4e ranitidine qh ah | ||
| ZT4.36.2e famotidine qh ah | ||
| ZT4.38e cimetidine qh ah | ||
| ZT6.4.2.8.34e omeprazole qh ah |
| YT10.10e | . . bile acids and salts qh |
| NT | EB26e bile acid metabolism qh ah | |
| +ZV10.2e cholic acid qh ah | ||
| ZV10.2.2.2e chenodeoxycholic acid qh ah | ||
| RT | XM6.6e bile qh ah | |
| +ZV10e cholanes qh ah |
| YT10.12 | . . cathartics qh |
| YT10.14 | . . antisecretory agents qh |
| ST | antisecretory drugs | |
| NT | ZT4.12.4e ranitidine qh ah | |
| ZT4.38e cimetidine qh ah | ||
| ZT6.4.2.8.34e omeprazole qh ah |
| YT12e | . urinary system agents qh |
| YT12.2 | . . urinary anti-infective agents qh |
| NT | +ZT4.12.2e nitrofuran qh ah | |
| BT | +YQ4e anti-infective agents qh ah |
| YT12.4 | . . renal agents qh |
| YT12.4.2e | . . . diuretics qh |
| HN | ETOH descriptor 1995. | |
| NT | YG34.2.2 spironolactone qh ah |
| YT14e | . hematologic agents qh |
| YT14.2e | . . anticoagulants qh |
| ST | anticoagulant drugs | |
| NT | ZO6.8.12.12e protein C qh ah | |
| RT | EE16.6e antagonistic drug interaction qh ah |
| YT14.4e | . . coagulants qh |
| RT | +ZO6.4.10.6.4e blood coagulation factors qh ah |
| YT14.6 | . . platelet aggregation inhibitors qh |
| HN | Introduced 1995. | |
| NT | ZJ2.10.10.2.4.2.2e acetylsalicylic acid qh ah | |
| ZK4.4.8.2e prostacyclin qh ah | ||
| ZT6.20.2e ketanserin qh ah |
| YT14.6.2 | . . . hemostatics qh |
| NT | YC4.10.4.8.4e thrombin qh ah |
| YT14.6.4 | . . . heparin antagonists qh |
| NT | YB18e vitamin K qh ah | |
| RT | EE16.6e antagonistic drug interaction qh ah |
| YT14.8e | . . fibrinolytic agents qh |
| HN | ETOH descriptor 2000. | |
| ST | antithrombotic agents | |
| NT | YC4.10.4.4e plasminogen activator qh ah | |
| YC4.10.4.8.12 streptokinase qh ah | ||
| YC18.2e plasminogen qh ah |
| YT14.10 | . . hematinics qh |
| NT | +YB12.24e vitamin B12 qh ah |
| YT14.12 | . . plasma substitutes qh |
| NT | ZH10e pectin qh ah |
| YV | . peripheral nervous system agents d-out qh |
| HN | Introduced 1995. | |
| SN | Many of these agents also have secondary effects on the central nervous system. | |
| BT | +YTe agents used in body system disorders qh ah |
| YV2 | . . bronchodilator agents qh |
| ST | bronchodilators | |
| NT | BC4 theophylline qh ah | |
| +YH2.2.6e epinephrine qh ah | ||
| ZN2.16.2.4e phenylephrine qh ah |
| YV4 | . . neuroregulators qh |
| NT | +YH2.2.6e epinephrine qh ah | |
| +YH2.2.6.6e norepinephrine qh ah | ||
| YH2.4.36e cholecystokinin qh ah | ||
| +ZJ2.6.10.2.2e aminobutyric acid qh ah | ||
| +ZN2.18.2e acetylcholine qh ah | ||
| +ZO4.24e neuropeptides qh ah | ||
| ZO4.24.4.4.2e substance P qh ah | ||
| +ZQ20.2e endorphins qh ah | ||
| ZT6.10.12.4e serotonin qh ah | ||
| RT | +YJ2e neurotransmitters qh ah |
| YV4.2 | . . . dopaminergic agents qh |
| NT | +ZN2.8.4e dopa qh ah | |
| +ZN2.8.6e dopamine qh ah | ||
| ZP32.2e apomorphine qh ah | ||
| ZT6.12.6e nomifensine qh ah |
| YV6 | . . neuroregulator blockaders qh |
| ST | neuroregulator blockers | |
| NT | +YT10.2e emetic agents qh ah | |
| RT | +YP10.8.6 cocaine blockers qh ah |
| YV6.2 | . . . antiemetics qh |
| ST | anti-emetic agents | |
| NT | ZT8.14.10e promethazine qh ah |
| YV6.4e | . . . histamine antagonists qh |
| RT | EE16.6e antagonistic drug interaction qh ah |
| YV6.4.2e | . . . . histamine H1 receptor blockaders qh |
| SN | A group of therapeutic drugs used in the treatment of allergic disorders (and sometimes, because of their mild sedating effects, to allay anxiety and induce sleep). Usually they are abused with codeine or alcohol because they act synergistically to magnify the sedative effects of both. | |
| ST | antihistamines | |
| antihistaminics | ||
| H1 blockers | ||
| NT | ZT4.26.2.2e pyrilamine qh ah | |
| ZT4.26.2.4e tripelennamine qh ah | ||
| ZT8.14.10e promethazine qh ah | ||
| BT | +YW4.8e sedative-hypnotics qh ah | |
| RT | +YW4.8.4e nonbarbiturate sedative-hypnotics qh ah |
| YV6.4.4e | . . . . histamine H2 receptor blockaders qh |
| ST | H2 blockers | |
| NT | ZT4.12.4e ranitidine qh ah | |
| ZT4.36.2e famotidine qh ah | ||
| ZT4.38e cimetidine qh ah |
| YV6.6e | . . . serotonin antagonists qh |
| SN | Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists. | |
| ST | 5-HT antagonists | |
| 5-hydroxytryptamine antagonists | ||
| NT | BF4.2e LSD qh ah | |
| +BF10 bufotenine qh ah | ||
| ZN2.10.6e phenoxybenzamine qh ah | ||
| ZO2.2.2.12.2 fenclonine qh ah | ||
| ZT4.28.6.2e risperidone qh ah | ||
| ZT4.28.6.4e ritanserin qh ah | ||
| ZT6.10.12.2e N,N-Dimethyltryptamine qh ah | ||
| ZT6.20.2e ketanserin qh ah | ||
| ZT8.4.2.2e clozapine qh ah | ||
| RT | EE16.6e antagonistic drug interaction qh ah | |
| ZT6.10.12.4e serotonin qh ah |
| YV6.6.2e | . . . . serotonin uptake inhibitors qh |
| SN | A group of drugs that inhibit neuronal re-uptake of serotonin, and consequently prolong its action. Such drugs have been reported to cause a reduction in alcohol consumption. Certain antidepressants share the property of inhibiting serotonin uptake, while also inhibiting noradrenaline (norepinephrine) uptake. | |
| ST | 5 HT sub 2 | |
| 5 HT sub 3 | ||
| 5-hydroxytryptamine uptake inhibitors | ||
| serotonin receptor inhibitors | ||
| serotonin reuptake inhibitors | ||
| NT | ZF8.6.2.2.2e sertraline qh ah | |
| ZN2.4.2e fluoxetine qh ah | ||
| ZN2.4.4e citalopram qh ah | ||
| ZN2.12e fluvoxamine qh ah | ||
| ZT4.14.10 ondansetron qh ah | ||
| ZT4.18.4e trazodone qh ah | ||
| ZT4.20.2e paroxetine qh ah | ||
| +ZT4.26.4.2.2e zimelidine qh ah | ||
| ZT8.6.2.2e amoxapine qh ah | ||
| BT | +YP4.8.2.2e serotonergic anti-alcohol-craving agents qh ah | |
| +YP4.8.12.6 agents for alcohol-concurrent depression qh ah | ||
| +YP4.8.12.10 agents for alcohol-related cognitive impairment qh ah |
| YV6.6.2.2 | . . . . . viqualine qh |
| BT | +YP4.8.2.2e serotonergic anti-alcohol-craving agents qh ah |
| YV6.6.2.4 | . . . . . amterozide qh |
| BT | +YP4.8.2.10 neuropeptide anti-alcohol-craving agents qh ah |
| YV8e | . . parasympatholytics qh |
| HN | ETOH descriptor 2000. | |
| ST | anticholinergic agents | |
| anticholinergics | ||
| NT | +YD10.2 cholinesterase reactivators qh ah | |
| ZJ2.10.4.4.2e quinuclidinyl benzilate qh ah | ||
| +ZP18e solanaceous alkaloids qh ah | ||
| ZP18.6.4e nicotinamide qh ah | ||
| +ZQ12.2e papaverine qh ah | ||
| BT | +YW8e CNS stimulants qh ah |
| YV8.2 | . . . ganglionic blockaders qh |
| ST | ganglionic blockers | |
| NT | BD2e nicotine qh ah | |
| ZU6.2e mecamylamine qh ah |
| YV10e | . . parasympathomimetics qh |
| HN | ETOH descriptor 2000. | |
| SN | A substance that produces actions similar to the stimulation of the parasympathetic nervous system. Also called cholinomimetic. | |
| ST | cholinomimetic | |
| NT | +YD8.4 cholinesterase inhibitors qh ah | |
| ZP12e physostigmine qh ah |
| YV10.2e | . . . carbachol qh |
| HN | Introduced 1995. |
| YV10.4 | . . . ganglionic stimulants qh |
| NT | BD2e nicotine qh ah | |
| ZP14e pilocarpine qh ah | ||
| ZT4.32.2.2e tremorine qh ah | ||
| ZT4.32.6.2e oxotremorine qh ah |
| YV12e | . . sympatholytics qh |
| HN | ETOH descriptor 2000. | |
| RT | +YK6.2e adrenergic receptors qh ah |
| YV12.2e | . . . alpha-adrenergic receptor blockaders qh |
| ST | alpha-2 adrenergic antagonists | |
| NT | ZN2.10.6e phenoxybenzamine qh ah | |
| ZP26.4e yohimbine qh ah | ||
| ZT4.14.12e phentolamine qh ah | ||
| ZT4.14.14e tolazoline qh ah | ||
| ZT6.20.6e prazosin qh ah | ||
| RT | +YK6.2e adrenergic receptors qh ah |
| YV12.4e | . . . beta-adrenergic receptor blockaders qh |
| NT | ZN2.16.2.6e sotalol qh ah | |
| ZN2.16.2.12.4.2e propranolol qh ah | ||
| RT | +YK6.2e adrenergic receptors qh ah |
| YV12.6 | . . . adrenergic neurohumor depleters qh |
| NT | +ZP26e rauwolfia alkaloids qh ah | |
| RT | +YK6.2e adrenergic receptors qh ah |
| YV14e | . . sympathomimetics qh |
| HN | ETOH descriptor 2000. | |
| SN | A drug that primarily mimics or produces effects similar to those resulting from stimulation of the sympathetic nervous system. Sympathomimetic drugs that also excite the central nervous system (CNS), such as the amphetamines, are used as recreational drugs. Also called adrenomimetic drugs. | |
| ST | adrenomimetic drugs | |
| NT | +ZN2.10.2e fenfluramine qh ah | |
| +ZN2.18.2.2.4e tyramine qh ah | ||
| RT | +YK6.2e adrenergic receptors qh ah |
| YV14.2e | . . . adrenergic receptor agonists qh |
| RT | EE16.4e synergistic drug interaction qh ah |
| YV14.2.2e | . . . . alpha-adrenergic receptor agonists qh |
| ST | alpha adrenergic agonists | |
| NT | +YH2.2.6e epinephrine qh ah | |
| +YH2.2.6.6e norepinephrine qh ah | ||
| ZN2.16.2.4e phenylephrine qh ah | ||
| RT | +YP4.6e alcohol withdrawal agents qh ah |
| YV14.2.2.2 | . . . . . adrenergic alpha-2 adrenergic agonists qh |
| YV14.2.4e | . . . . beta-adrenergic receptor agonists qh |
| NT | +YH2.2.6.6e norepinephrine qh ah | |
| ZN2.16.2.14e ritodrine qh ah | ||
| +ZQ12.2.2e papaveroline qh ah |
| YV14.4e | . . . neurotransmitter uptake inhibitors qh |
| HN | ETOH descriptor 2000. | |
| ST | neuronal transmitter uptake inhibitors | |
| RT | EE16.6e antagonistic drug interaction qh ah | |
| +EW6e neurotransmission qh ah | ||
| +YJ2e neurotransmitters qh ah |
classification thesaurus glossary dictionary definition subject heading list ontology vocabulary knowledge structure knowledge organization terminology concept